Published in Eur J Heart Fail on November 28, 2012
Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? Cardiol Res Pract (2013) 0.81
Cardiac structural remodeling in hypertensive cardiomyopathy. Hypertens Res (2016) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med (2004) 6.00
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol (2010) 3.50
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol (2009) 3.31
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Common variants near TERC are associated with mean telomere length. Nat Genet (2010) 2.98
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J (2005) 2.81
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J (2005) 2.74
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail (2012) 2.72
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J (2010) 2.68
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation (2009) 2.60
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol (2012) 2.60
Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol (2008) 2.59
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail (2009) 2.51
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J (2013) 2.45
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation (2010) 2.41
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.36
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 2.35
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med (2009) 2.31
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 2.30
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J (2012) 2.29
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J (2008) 2.26
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med (2008) 2.23
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
Endogenous erythropoietin and outcome in heart failure. Circulation (2010) 2.19
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol (2007) 2.15
What works in chronic care management: the case of heart failure. Health Aff (Millwood) (2009) 2.11